News
3d
Zacks Investment Research on MSNNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of ...
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill.
The Wegovy maker’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14%, according to a new trial.
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates.
LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market ...
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped ...
Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results